Recombinant activated factor VII (rFVIIa, NovoSeven®)

M. B. Agarwal, Mrinal M Patnaik

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Recombinant activated factor VII (rFVIIa, NovoSeven®) enhances haemostasis in individuals, with its predominant action limited to areas of injury, apparently without systemic activation of the coagulation cascade. rFVIIa is currently licensed in most countries worldwide, for its use in the treatment of bleeding episodes in patients with hemophilia and the presence of inhibitors. Recently in the European Union, rFVIIa, has been approved for use in congenital Factor VII deficiency and Glanzmann's thrombasthenia. Furthermore, a large number of case series studies and anecdotal evidences, from patients with different bleeding conditions, have now shown that rFVIIa is actually a very valuable general haemostatic agent. It has been reported to reduce bleeding in patients with liver disease, thrombocytopenia/thrombocytopathia, trauma, spontaneous intracerebral hemorrhage and in the reversal of anticoagulant overdosage or toxicity. A number of trials have been carried out, which have shown that it is a relatively safe and well tolerated drug with a few episodes of unwanted thrombosis.

Original languageEnglish (US)
Pages (from-to)717-720
Number of pages4
JournalJournal of Association of Physicians of India
Volume53
Issue numberAUG
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Factor VIIa
Hemorrhage
Factor VII Deficiency
Thrombasthenia
Cerebral Hemorrhage
Wounds and Injuries
Hemophilia A
Hemostatics
European Union
Hemostasis
Thrombocytopenia
Anticoagulants
Liver Diseases
Thrombosis
recombinant FVIIa
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Recombinant activated factor VII (rFVIIa, NovoSeven®). / Agarwal, M. B.; Patnaik, Mrinal M.

In: Journal of Association of Physicians of India, Vol. 53, No. AUG, 08.2005, p. 717-720.

Research output: Contribution to journalReview article

@article{71e78b2413a2431f9bf5e676c67a4053,
title = "Recombinant activated factor VII (rFVIIa, NovoSeven{\circledR})",
abstract = "Recombinant activated factor VII (rFVIIa, NovoSeven{\circledR}) enhances haemostasis in individuals, with its predominant action limited to areas of injury, apparently without systemic activation of the coagulation cascade. rFVIIa is currently licensed in most countries worldwide, for its use in the treatment of bleeding episodes in patients with hemophilia and the presence of inhibitors. Recently in the European Union, rFVIIa, has been approved for use in congenital Factor VII deficiency and Glanzmann's thrombasthenia. Furthermore, a large number of case series studies and anecdotal evidences, from patients with different bleeding conditions, have now shown that rFVIIa is actually a very valuable general haemostatic agent. It has been reported to reduce bleeding in patients with liver disease, thrombocytopenia/thrombocytopathia, trauma, spontaneous intracerebral hemorrhage and in the reversal of anticoagulant overdosage or toxicity. A number of trials have been carried out, which have shown that it is a relatively safe and well tolerated drug with a few episodes of unwanted thrombosis.",
author = "Agarwal, {M. B.} and Patnaik, {Mrinal M}",
year = "2005",
month = "8",
language = "English (US)",
volume = "53",
pages = "717--720",
journal = "Journal of Association of Physicians of India",
issn = "0004-5772",
publisher = "Journal of Association of Physicians of India",
number = "AUG",

}

TY - JOUR

T1 - Recombinant activated factor VII (rFVIIa, NovoSeven®)

AU - Agarwal, M. B.

AU - Patnaik, Mrinal M

PY - 2005/8

Y1 - 2005/8

N2 - Recombinant activated factor VII (rFVIIa, NovoSeven®) enhances haemostasis in individuals, with its predominant action limited to areas of injury, apparently without systemic activation of the coagulation cascade. rFVIIa is currently licensed in most countries worldwide, for its use in the treatment of bleeding episodes in patients with hemophilia and the presence of inhibitors. Recently in the European Union, rFVIIa, has been approved for use in congenital Factor VII deficiency and Glanzmann's thrombasthenia. Furthermore, a large number of case series studies and anecdotal evidences, from patients with different bleeding conditions, have now shown that rFVIIa is actually a very valuable general haemostatic agent. It has been reported to reduce bleeding in patients with liver disease, thrombocytopenia/thrombocytopathia, trauma, spontaneous intracerebral hemorrhage and in the reversal of anticoagulant overdosage or toxicity. A number of trials have been carried out, which have shown that it is a relatively safe and well tolerated drug with a few episodes of unwanted thrombosis.

AB - Recombinant activated factor VII (rFVIIa, NovoSeven®) enhances haemostasis in individuals, with its predominant action limited to areas of injury, apparently without systemic activation of the coagulation cascade. rFVIIa is currently licensed in most countries worldwide, for its use in the treatment of bleeding episodes in patients with hemophilia and the presence of inhibitors. Recently in the European Union, rFVIIa, has been approved for use in congenital Factor VII deficiency and Glanzmann's thrombasthenia. Furthermore, a large number of case series studies and anecdotal evidences, from patients with different bleeding conditions, have now shown that rFVIIa is actually a very valuable general haemostatic agent. It has been reported to reduce bleeding in patients with liver disease, thrombocytopenia/thrombocytopathia, trauma, spontaneous intracerebral hemorrhage and in the reversal of anticoagulant overdosage or toxicity. A number of trials have been carried out, which have shown that it is a relatively safe and well tolerated drug with a few episodes of unwanted thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=24644465093&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644465093&partnerID=8YFLogxK

M3 - Review article

C2 - 16398083

AN - SCOPUS:24644465093

VL - 53

SP - 717

EP - 720

JO - Journal of Association of Physicians of India

JF - Journal of Association of Physicians of India

SN - 0004-5772

IS - AUG

ER -